Coronary-artery stents.

At present, 90 to 95 percent of percutaneous coronary interventions involve the implantation of a stent, often a drug-eluting stent, though most published data originated in the era of bare-metal stents. This article reviews the indications for and biology of coronary-artery stents, focusing on recent advances in drug-eluting stents.

[1]  P. Tsao,et al.  Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. , 2004, Cardiovascular research.

[2]  Christoph Kaiser,et al.  Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET) , 2005, The Lancet.

[3]  A. Kastrati,et al.  Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. , 2002, Journal of the American College of Cardiology.

[4]  Bruce R. Brodie,et al.  Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction , 1999 .

[5]  P. Serruys,et al.  Arterial Revascularisation Therapies Study Part II - Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. , 2005, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[6]  P. Serruys,et al.  Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. , 1994, American heart journal.

[7]  P. Serruys,et al.  Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era. , 2006, American heart journal.

[8]  A James O'Malley,et al.  Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. , 2005, The American journal of cardiology.

[9]  Antonio Colombo,et al.  Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions , 2004, Circulation.

[10]  J. Brophy,et al.  Evidence for Use of Coronary Stents: A Hierarchical Bayesian Meta-Analysis , 2003, Annals of Internal Medicine.

[11]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[12]  N. Weissman,et al.  A paclitaxel-eluting stent for the prevention of coronary restenosis. , 2003, The New England journal of medicine.

[13]  P. Serruys,et al.  Intravascular Ultrasound Findings in the Multicenter, Randomized, Double-Blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) Trial , 2002, Circulation.

[14]  M. Bertrand,et al.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.

[15]  Larry S. Dean,et al.  Intracoronary Stenting for Acute and Threatened Closure Complicating Percutaneous Transluminal Coronary Angioplasty , 1992, Circulation.

[16]  F. Eberli,et al.  Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.

[17]  F. Eberli,et al.  Randomized Comparison of a Titanium-Nitride-Oxide–Coated Stent With a Stainless Steel Stent for Coronary Revascularization: The TiNOX Trial , 2005, Circulation.

[18]  Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. , 2004, Journal of the American College of Cardiology.

[19]  Patrick W Serruys,et al.  Four-Year Angiographic and Intravascular Ultrasound Follow-Up of Patients Treated With Sirolimus-Eluting Stents , 2005, Circulation.

[20]  Takuji Nakamura,et al.  Biodegradable stents as a platform to drug loading , 2003, International journal of cardiovascular interventions.

[21]  Klaus Rasmussen,et al.  A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. , 2003, The New England journal of medicine.

[22]  C. Vrints,et al.  Study of antirestenosis with the BiodivYsio dexamethasone‐eluting stent (STRIDE): A first‐in‐human multicenter pilot trial , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[23]  Patrick W Serruys,et al.  The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. , 2006, American heart journal.

[24]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[25]  Muzaffer Degertekin,et al.  TAXUS III Trial: In-Stent Restenosis Treated With Stent-Based Delivery of Paclitaxel Incorporated in a Slow-Release Polymer Formulation , 2003, Circulation.

[26]  A. Heldman,et al.  Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary Stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) Trial , 2004, Circulation.

[27]  N. Krott,et al.  Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. , 2004, European heart journal.

[28]  P. Buser,et al.  Incremental Cost-Effectiveness of Drug-Eluting Stents Compared With a Third-Generation Bare-Metal Stent in a Real-World Setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET) , 2005 .

[29]  J. Popma,et al.  The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). , 2004, Journal of the American College of Cardiology.

[30]  M. Leon,et al.  Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. , 1997, The New England journal of medicine.

[31]  P Serruys,et al.  Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. , 1998, The New England journal of medicine.

[32]  F Joffre,et al.  Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.

[33]  J. J. Griffin,et al.  Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. , 2002, The New England journal of medicine.

[34]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[35]  G. Stone,et al.  Randomized Comparison of Distal Protection With a Filter-Based Catheter and a Balloon Occlusion and Aspiration System During Percutaneous Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts , 2003, Circulation.

[36]  B Meier,et al.  Angiographic follow-up after placement of a self-expanding coronary-artery stent. , 1991, The New England journal of medicine.

[37]  P. Serruys,et al.  Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. , 2005, Journal of the American College of Cardiology.

[38]  C. Di Mario,et al.  Randomized Evaluation of Polytetrafluoroethylene‐Covered Stent in Saphenous Vein Grafts: The Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial , 2003, Circulation.

[39]  P. Barragan,et al.  Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures. , 2000, Journal of the American College of Cardiology.

[40]  Raimund Erbel,et al.  Coronary-Artery Stenting Compared with Balloon Angioplasty for Restenosis After Initial Balloon Angioplasty , 1999 .

[41]  P. Serruys,et al.  Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease: Insights From the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital Registries (RESEARCH and T-SEARCH) , 2005, Circulation.

[42]  B. Davis,et al.  Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial , 2002, Circulation.

[43]  S. Silber,et al.  Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.

[44]  Jan J Piek,et al.  A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. , 2005, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[45]  P. Serruys,et al.  A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions: final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study. , 2002, Journal of the American College of Cardiology.

[46]  Mary E. Russell,et al.  TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.

[47]  V. Fuster,et al.  Thoughts on the role of the healing professions and the events of September 11, 2001. , 2002, Circulation.

[48]  R. Virmani,et al.  Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. , 2003, Circulation.

[49]  J. Palmaz,et al.  Expandable intraluminal graft: a preliminary study. Work in progress. , 1985, Radiology.

[50]  Gregg W. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease , 2004 .

[51]  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000 .

[52]  W. Siegenthaler,et al.  Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.

[53]  P. Fitzgerald,et al.  Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable Polymer , 2004, Circulation.

[54]  A. Kastrati,et al.  Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. , 2005, JAMA.

[55]  M. Labinaz,et al.  Biodegradable stents: the future of interventional cardiology? , 1995, Journal of interventional cardiology.

[56]  C. Di Mario,et al.  Stented segment length as an independent predictor of restenosis. , 1999, Journal of the American College of Cardiology.

[57]  R A Schatz,et al.  Balloon-expandable intracoronary stents in the adult dog. , 1987, Circulation.

[58]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[59]  V. Fuster,et al.  Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model. , 2000, Atherosclerosis.

[60]  Seung‐Jung Park,et al.  Stenting of unprotected left main coronary artery stenoses: immediate and late outcomes. , 1998, Journal of the American College of Cardiology.

[61]  A. Kastrati,et al.  Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. , 2005, The New England journal of medicine.

[62]  M. Leon,et al.  Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass Grafts , 2002, Circulation.

[63]  A. Kastrati,et al.  Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. , 2000, Circulation.

[64]  Janita F. J. Vos,et al.  Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. , 2001, European heart journal.

[65]  Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. , 2005 .

[66]  P. Serruys,et al.  Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. , 2004, Journal of the American College of Cardiology.

[67]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[68]  S Marx,et al.  Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. , 1999, Circulation.

[69]  E Regar,et al.  Stent development and local drug delivery. , 2001, British medical bulletin.

[70]  Antonio Colombo,et al.  Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) , 1998, The Lancet.

[71]  R. Whitbourn,et al.  First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. , 2005, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[72]  Patrick W Serruys,et al.  Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. , 2003, Journal of the American College of Cardiology.

[73]  Patrick W Serruys,et al.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.

[74]  J. Tobis,et al.  Bifurcation lesions: two stents versus one stent--immediate and follow-up results. , 2000, Journal of the American College of Cardiology.

[75]  P. Serruys,et al.  Radioactive Stents Delay but Do Not Prevent In-Stent Neointimal Hyperplasia , 2001, Circulation.

[76]  P. Serruys,et al.  Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. , 2005, Journal of the American College of Cardiology.

[77]  H. Suryapranata,et al.  Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. , 1998, Circulation.

[78]  P. Serruys,et al.  CORONARY ARTERY DISEASE Original Studies Clinical Outcomes for Sirolimus-Eluting Stent Implantation and Vascular Brachytherapy for the Treatment of In-Stent Restenosis , 2004 .

[79]  P Hall,et al.  Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. , 1995, Circulation.

[80]  Marco Valgimigli,et al.  The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. , 2005, Journal of the American College of Cardiology.

[81]  S. Silber,et al.  High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. , 2004, Journal of the American College of Cardiology.

[82]  A Haverich,et al.  Left main coronary artery fistula exiting into the right atrium , 2003, Heart.

[83]  I. Iakovou,et al.  Early and Mid-Term Results of Drug-Eluting Stent Implantation in Unprotected Left Main , 2005, Circulation.

[84]  C. Di Mario,et al.  Intravascular ultrasound-guided percutaneous transluminal coronary angioplasty with provisional spot stenting for treatment of long coronary lesions. , 2001, Journal of the American College of Cardiology.

[85]  Patrick W Serruys,et al.  Late angiographic stent thrombosis (LAST) events with drug-eluting stents. , 2005, Journal of the American College of Cardiology.

[86]  J. Moses,et al.  Sirolimus-eluting stents vs. standard stents in patients with stenosis in a native coronary artery , 2004 .

[87]  Patrick W Serruys,et al.  Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. , 2005, Journal of the American College of Cardiology.

[88]  M. P. Judkins,et al.  Transluminal Treatment of Arteriosclerotic Obstruction: Description of a New Technic and a Preliminary Report of Its Application , 1964, Circulation.

[89]  T. Harr,et al.  Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. , 2004, The American journal of medicine.

[90]  Patrick W Serruys,et al.  Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin-E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry , 2004, Circulation.

[91]  M. Lauer,et al.  Reduction of subacute stent thrombosis (SAT) using heparin-coated stents in a large-scale, real world registry. , 2004, The Journal of invasive cardiology.

[92]  M. Morice,et al.  Stenting of bifurcation lesions: a rational approach. , 2001, Journal of interventional cardiology.

[93]  H. Uehata,et al.  Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.

[94]  F. Neumann,et al.  Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. , 1996, Circulation.

[95]  K. Hauptmann,et al.  Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating. , 2005, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[96]  G. Stone,et al.  Non–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions: Angiographic Follow-Up of the DELIVER Clinical Trial , 2004, Circulation.

[97]  M. Aschermann,et al.  Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. , 2003, European heart journal.

[98]  William Wijns,et al.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) , 2003, The Lancet.

[99]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[100]  Patrick W Serruys,et al.  Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. , 2004, Journal of the American College of Cardiology.